Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Egis Gyogyszergyar Zrt.

Onp Holdings Se

Egis Gyogyszergyar Rt.

Gyula Lukács

Tibor Mezei

Márta Porcs-Makkay

Gyula Simig

Balázs Volk

Kálmán Nagy

Zoltán Varga

József Barkóczy

György Lévay

László Szlávik

Péter Trinka

Endre Mikulásik

Adrienn Keszthelyi

Györgyi Vereczkeyné Donáth

Gábor Gigler

Enikó Molnár

Tamás Spaits

Tibor Szabó

Gábor Berecz

Gyuláné Körtvélyessy

Mátyás Milen

János Szulágyi

Éva Pécsi

László Pongó

Zoltán Katona

Hajnalka Kompagne

Norbert Mesterházy

Imre Markovits

György Clementis

Imre Kapui

Angéla Pandur

Krisztina Fodorné Kocsmár

Gitta Kiss

Beatrix Bánkövi

László Ugrai

György Ruzsics

Enikö Molnár

Zsuzsanna Évinger

József Debreczeni

Angéla Veressné Pandur

Livia Gregorné Boros

György Krasznai

Ottó Albrecht

Gábor Attila Bacher

Mária Vajjon

Réka Eszter Puskás

Gyöngyi Heréb

Máté Hudák

Tamás Mórász

Valéria Hofmanné Fekete

András Boza

Mária Júlia TÁBORINE TÓTH

Ferenc Lóránt Bartha

Maria TÓTHNÉ Lauritz

Tibor SzabÓ

Endre MIKULÁSIK

Mária KOVÁCS

Laszló PongÓ

Imre KIRÁLY

Ildikó Nagyné Gyönös

István Gacsalyi

József Schindler

Jószef Barkóczy

Enikõ Molnár

László József HEGEDÜS

Györgyi KOVÁNYINÉ Lax

Balázs Peregi

Ede László MÁRVÁNYOS

János Levente HÉDER

Róbert Gudor

László Palotai

Róbert KORMÁNY

András DancsÓ

Mária TÓTHNÉ Lauritz

Katalin KÁTAINÉ Fadgyas

ÉVa Sipos

Balázs Havasi

A pharmaceutical composition containing palbociclib tosylate and letrozole, in which palbociclib tosylate and letrozole are in one dosage unit, and the particles of the active ingredient palbociclib tosylate and letrozole are not separated from each other, and the production of the pharmaceutical preparation, the granule containing palbociclib tosylate and letrozole, the use of the pharmaceutical preparation and special blister packaging that facilitates the use of a specific dosage regimen.

Pharmaceutical composition containing palbociclib and letrozole

A method for purifying diatomaceous earth, whose natural colloidal structure is retained, which includes preparing a suspension of diatomaceous earth in a liquid wherein diatomaceous earth is insoluble, separating diatomaceous earth from the suspension, treating diatomaceous earth with an inorganic or organic acid, heat-treating the thus obtained product at a temperature not higher than 300&#xb0; C., subjecting the product obtained to oxidative treatment and drying the purified product.

Method for purifying diatomaceous earth

The invention relates to a process for the preparation of cyclopropyl benzyl ketone compounds of formula (II) wherein Rrepresents fluorine or chlorine atom or Calkoxy group, by the reaction of a Grignard reagent, obtained from the reaction of compound of formula (V), wherein X represents chlorine or fluorine atom, with the compound of formula (IV), wherein Rrepresents Calkyl group, having a straight or branched chain. The process can be applied preferably on industrial scale. Compound of formula (II), wherein R represents a fluorine atom in position 2 is an intermediate of the preparation process of prasugrel, which is a platelet inhibitor used in the therapy. 

Process for the preparation of pharmaceutical intermediates

The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium sait monohydrate is produced. Said sait is subsequently treated with mineral or organic acid to yield high-purity meloxicam.

Process for preparation of high-purity meloxicam and meloxicam potassium salt

The compounds of the general Formula (I), wherein Ris aryl or alkyl; Rrepresents alkyl; Rrepresents alkyl or aralkyl, are valuable pharmaceutical intermediates, which can be prepared by reacting a compound of the general Formula (IV) (wherein the definitions of Rand Rare as above), with at least 2 molar equivalents of the compound of the general Formula (VI) (wherein X represents halogen or tertiary butyloxycarbonyloxy group and Ris as defined above). The known compounds of the general Formula (II) (wherein Rand Rare as defined above) are prepared by reacting the compounds of the general Formula (I) with thionyl chloride. The compounds of the general Formula (I) are new intermediates useful in the synthesis of pharmaceutically active ingredients, particularly in the preparation of ACE-inhibitors, e.g. enalapril, perindopril or ramipril.

Pharmaceutical intermediate for synthesizing ACE inhibitors and the use thereof

Growing community of inventors

Budapest, Hungary

Gyula Lukács